Telesta Therapeutics Inc.

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Aug. 13 and Aug. 29.

FDA’s Center for Drug Evaluation and Research approved 14 new molecular entities and novel therapeutic biologics in the first half of 2016 – the same number of novel approvals as in the first half of

Heat Biologics Inc. is doing everything it can to keep going with its Phase II bladder cancer immunotherapy, announcing several cost-reduction measures April 7, but it will be tough going in a crowd

FDA non-approval actions took center stage this week, with the announcement of two complete response letters – one for a novel biologic cancer therapy and the other for expansion of the rare genetic s